law.justia.com/cases/federal/district-courts/illinois/ilndce/1:2016cv07142/329069/59

Mar 14, 2019 ... United States of America et al v. Pfizer, Inc. et al, No. 1:2016cv07142 - Document 59 (N.D. Ill. 2019) case opinion from the Northern District of ...

law.justia.com/cases/federal/appellate-courts/ca1/16-1805/16-1805-2017-01-30.html

Jan 30, 2017 ... In 2009, Pfizer, settled claims that it had violated the False Claims Act ... All of these claims were resolved against relators, one on a motion to ...

www.pacermonitor.com/public/case/27866570/Johnson_et_al_v_Pfizer_Inc_et_al

6 days ago ... Johnson et al v. Pfizer Inc. et al (1:19-cv-03431), New York Southern District Court, Filed: 04/17/2019 - PacerMonitor Mobile Federal and ...

www.plainsite.org/dockets/lalwlh4a/new-york-southern-district-court/coultrip-et-al-v-pfizer-inc

Coultrip et al v. Pfizer, Inc, Case No. 1:06-cv-09952 in the New York Southern District Court.

www.ncbi.nlm.nih.gov/pubmed/26149717

(1)Probity Medical Research and K Papp Clinical Research Inc., 135 Union Street East, Waterloo, ON, N2J 1C4, Canada. ... (4)University of Alabama, Tuscaloosa, AL, U.S.A. ... (10)Pfizer Inc., Groton, CT, U.S.A. ... Higher PASI 75 rates were observed with tofacitinib vs. placebo (OPT Pivotal 1, 39·9%, 59·2% and 6·2%, ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC3365537

Jun 1, 2012 ... Barbershop-based hypertension (HTN) outreach programs for black ..... (P=0.22) but tended to be lower in the intervention group (33.8% vs. .... Financial Disclosures: Dr. Victor reported being on the speaker's Bureau for Pfizer, Inc. and receiving an investigator .... Victor RG, Ravenell JE, Freeman A, et al.

www.ncbi.nlm.nih.gov/pmc/articles/PMC4285807

For all HZ cases occurring in the Tofacitinib RA Development Program, we collected ..... Pfizer Inc. facilitated the phase II, phase III, and LTE clinical trials in the Tofacitinib RA .... et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. ... Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al.

jamanetwork.com/journals/jamainternalmedicine/fullarticle/226700

Oct 25, 2010 ... All 18 initially agreed to participate, but 1 shop went out of business .... in the intervention group (33.8% vs 40.0%) (Table 2 and Figure 3). .... Financial Disclosure: Dr Victor has served on the speaker's bureau for Pfizer Inc and received an investigator-initiated ... Lloyd-Jones DAdams RCarnethon M et al.

dmd.aspetjournals.org/content/43/4/490

Apr 1, 2015 ... ... Global Innovative Pharma Business (J.A.C.), Pfizer Inc., Groton, ..... (SNP) of BCRP that results in reduced activity (Giacomini et al., 2013). ..... versus IR tablet but was not statistically significant (Urquhart et al., 2008; Kusuhara et al., 2012). ...... Farrell TL,; Poquet L,; Dew TP,; Barber S, and; Williamson G.